Kesch, Claudia http://orcid.org/0000-0002-2656-2664
Yirga, Leubet
Dendl, Katharina
Handke, Analena
Darr, Christopher
Krafft, Ulrich
Radtke, Jan Philipp
Tschirdewahn, Stephan
Szarvas, Tibor
Fazli, Ladan
Gleave, Martin
Giesel, Frederik L.
Haberkorn, Uwe
Hadaschik, Boris
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 14 March 2021
Accepted: 19 May 2021
First Online: 5 July 2021
Decalrations
:
: Retrospective patient data analysis was approved by the Ethics Committee of the University Hospital Heidelberg (S016/2018). TMA data analysis and biobank were approved by the University of British Columbia, Office of Research Ethics, Clinical Research Ethics Board (UBC CRBE number H09-01,628).
: BH reports personal fees and non-financial support from Bayer; personal fees and non-financial support from BMS; personal fees and non-financial support from AstraZeneca; personal fees from Pfizer; personal fees and non-financial support from Lightpoint Medical, Inc.; personal fees from ABX; grants from German Research Foundation; and personal fees and non-financial support from Janssen, all outside the submitted work. JPR reports personal fees and non-financial support from Janssen, personal fees and non-financial support from Dr. Wolf, Beckelmann&Partner personal fees and non-financial support from Bayer Healthineers, and personal fees and non-financial support from Saegeling Medizintechnik. UH and FLG have a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. UH and FLG also have shares of a consultancy group for iTheranostics. FLG is a medical advisor for ABX Advanced Biochemical Compound, Sofie Biosciences, and Telix Pharmaceuticals. The other authors declare no competing interests.